• Je něco špatně v tomto záznamu ?

Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment

A. Fahrleitner-Pammer, D. Burr, H. Dobnig, JJ. Stepan, H. Petto, J. Li, JH. Krege, I. Pavo,

. 2016 ; 89 (-) : 16-24. [pub] 20160513

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18017249

An increase in procollagen type I amino-terminal propeptide (PINP) early after teriparatide initiation was shown to correlate with increased lumbar spine areal BMD and is a good predictor of the anabolic response to teriparatide. Few data exist correlating PINP and bone microstructure, and no data exist in patients on teriparatide following prior potent antiresorptive treatment. This exploratory analysis aimed to investigate the effects of teriparatide on cancellous bone microstructure and correlations of bone markers with microstructure in alendronate-pretreated patients. This was a post hoc analysis of changes in bone markers and three-dimensional indices of bone microstructure in paired iliac crest biopsies from a prospective teriparatide treatment study in postmenopausal women with osteoporosis who were either treatment-naïve (TN, n=16) or alendronate-pretreated (ALN, n=29) at teriparatide initiation. Teriparatide (20μg/day) was given for 24months; biopsies were taken at baseline and endpoint, and serum concentrations of PINP and type 1 collagen cross-linked C-telopeptide (βCTX) were measured at intervals up to 24months. In the TN and ALN groups, respectively, mean (SD) increases in three-dimensional bone volume/tissue volume were 105 (356)% (P=0.039) and 55 (139)% (P<0.005) and trabecular thickness 30.4 (30)% (P<0.001) and 30.8 (53)% (P<0.001). No significant changes were observed in trabecular number or separation. In the ALN patients, 3-month change of neither PINP nor βCTX correlated with indices of cancellous bone microstructure. However, 12-month changes in biochemical bone markers correlated significantly with improvements in bone volume/tissue volume, r=0.502 (P<0.01) and r=0.378 (P<0.05), trabecular number, r=0.559 (P<0.01) and r=0.515 (P<0.01), and reduction of trabecular separation, r=-0.432 (P<0.05) and r=-0.530 (P<0.01), for PINP and βCTX, respectively. We conclude that cancellous bone microstructure improved with teriparatide therapy irrespective of prior antiresorptive use.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017249
003      
CZ-PrNML
005      
20180521123059.0
007      
ta
008      
180515s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bone.2016.05.004 $2 doi
035    __
$a (PubMed)27185100
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fahrleitner-Pammer, Astrid $u Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria. Electronic address: astrid.fahrleitner@medunigraz.at.
245    10
$a Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment / $c A. Fahrleitner-Pammer, D. Burr, H. Dobnig, JJ. Stepan, H. Petto, J. Li, JH. Krege, I. Pavo,
520    9_
$a An increase in procollagen type I amino-terminal propeptide (PINP) early after teriparatide initiation was shown to correlate with increased lumbar spine areal BMD and is a good predictor of the anabolic response to teriparatide. Few data exist correlating PINP and bone microstructure, and no data exist in patients on teriparatide following prior potent antiresorptive treatment. This exploratory analysis aimed to investigate the effects of teriparatide on cancellous bone microstructure and correlations of bone markers with microstructure in alendronate-pretreated patients. This was a post hoc analysis of changes in bone markers and three-dimensional indices of bone microstructure in paired iliac crest biopsies from a prospective teriparatide treatment study in postmenopausal women with osteoporosis who were either treatment-naïve (TN, n=16) or alendronate-pretreated (ALN, n=29) at teriparatide initiation. Teriparatide (20μg/day) was given for 24months; biopsies were taken at baseline and endpoint, and serum concentrations of PINP and type 1 collagen cross-linked C-telopeptide (βCTX) were measured at intervals up to 24months. In the TN and ALN groups, respectively, mean (SD) increases in three-dimensional bone volume/tissue volume were 105 (356)% (P=0.039) and 55 (139)% (P<0.005) and trabecular thickness 30.4 (30)% (P<0.001) and 30.8 (53)% (P<0.001). No significant changes were observed in trabecular number or separation. In the ALN patients, 3-month change of neither PINP nor βCTX correlated with indices of cancellous bone microstructure. However, 12-month changes in biochemical bone markers correlated significantly with improvements in bone volume/tissue volume, r=0.502 (P<0.01) and r=0.378 (P<0.05), trabecular number, r=0.559 (P<0.01) and r=0.515 (P<0.01), and reduction of trabecular separation, r=-0.432 (P<0.05) and r=-0.530 (P<0.01), for PINP and βCTX, respectively. We conclude that cancellous bone microstructure improved with teriparatide therapy irrespective of prior antiresorptive use.
650    _2
$a senioři $7 D000368
650    _2
$a alendronát $x terapeutické užití $7 D019386
650    _2
$a kostní denzita $x účinky léků $7 D015519
650    _2
$a inhibitory kostní resorpce $x terapeutické užití $7 D050071
650    _2
$a remodelace kosti $x účinky léků $7 D016723
650    _2
$a trabekulární kostní tkáň $x účinky léků $7 D000071556
650    _2
$a kolagen typu I $x krev $7 D024042
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a postmenopauzální osteoporóza $x farmakoterapie $7 D015663
650    _2
$a peptidové fragmenty $x krev $7 D010446
650    _2
$a peptidy $x krev $7 D010455
650    _2
$a prokolagen $x krev $7 D011347
650    _2
$a teriparatid $x terapeutické užití $7 D019379
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Burr, David $u Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
700    1_
$a Dobnig, Harald $u Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria.
700    1_
$a Stepan, Jan J $u Institute of Rheumatology and Faculty of Medicine 1, Charles University, Prague, Czech Republic.
700    1_
$a Petto, Helmut $u Lilly Research Centre, Vienna, Austria.
700    1_
$a Li, Jiliang $u Department of Biology, Indiana University Purdue University, Indianapolis, IN, USA.
700    1_
$a Krege, John H $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
700    1_
$a Pavo, Imre $u Lilly Research Centre, Vienna, Austria.
773    0_
$w MED00000833 $t Bone $x 1873-2763 $g Roč. 89, č. - (2016), s. 16-24
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27185100 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180521123241 $b ABA008
999    __
$a ok $b bmc $g 1300873 $s 1014089
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 89 $c - $d 16-24 $e 20160513 $i 1873-2763 $m Bone $n Bone $x MED00000833
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace